Peptide Association LLC is a for-profit company. We receive compensation from the clinical providers listed on this site. We are not an accrediting body, a licensing board, or a government-affiliated organization. See exactly how we make money.
MGF (Mechano Growth Factor)
Overview
Mechano Growth Factor is a splice variant of the IGF-1 gene expressed in response to mechanical stress on muscle tissue. The peptide contains a unique C-terminal domain resulting from alternative splicing that distinguishes it from systemic IGF-1.
Mechanism of Action
MGF is proposed to act locally in skeletal muscle to activate satellite cells and promote muscle fiber repair and hypertrophy following mechanical loading or injury.
Research Summary & Key Findings
Evidence derives primarily from rodent models demonstrating increased satellite cell activation and muscle regeneration following injection into damaged muscle tissue. No human clinical trials have been published, and pharmacokinetic parameters in humans remain undefined. The peptide is not approved for any medical indication.
Clinical Status
MGF (Mechano Growth Factor) is in the research phase with limited clinical data in humans. Current evidence is primarily derived from preclinical (animal or in vitro) studies.
Administration Routes
References
Primary literature
- PubMed: "MGF"
Peer-reviewed literature indexed by the National Library of Medicine.
- ClinicalTrials.gov: "MGF"
Registered interventional and observational studies, including status and phase.
- PubChem: "MGF"
Chemical structure, molecular properties, and bioactivity data.
Study-level citations for this compound are being verified against the primary sources before publication. The database queries above return the current indexed literature in the meantime.
Related Peptides in Performance
Melanotan II
Research PhaseA synthetic cyclic analog of alpha-melanocyte stimulating hormone (alpha-MSH) that non-selectively activates melanocorti...
View detailsIGF-1 LR3 (Long-Arg3)
Research PhaseIGF-1 LR3 is a synthetic analogue of insulin-like growth factor 1 with an N-terminal extension of 13 amino acids and a s...
View detailsIGF-1 DES (1-3)
Research PhaseIGF-1 DES (1-3) is a truncated analogue of insulin-like growth factor 1 lacking the first three N-terminal amino acids (...
View detailsPEG-MGF
Research PhasePEG-MGF is a pegylated derivative of Mechano Growth Factor designed to extend systemic half-life through the addition of...
View detailsNo lawful pathway today
MGF (Mechano Growth Factor) is not FDA-approved and does not currently have a lawful prescription or compounding pathway in the United States, so there is nothing for us to sell you here and no consultation to book. That can change: eight peptides moved back to a lawful pathway in February 2026.
Tell me if the status changes
One email, only if this compound's regulatory standing actually moves. Not a newsletter, not a sales sequence.
Join the Association
Access exclusive peptide protocols, provider resources, and community support.
List Your PracticeDisclaimer: This information is provided for educational and research purposes only. It is not intended as medical advice, diagnosis, or treatment. Always consult a qualified healthcare provider before starting any peptide therapy. The Peptide Association does not endorse or recommend any specific treatment protocol. See our editorial policy for how this content is produced and reviewed.